Leadership Transition at IFPMA: Dr. Thomas Schinecker Appointed President
| Aspect | Details |
|---|---|
| New IFPMA President | Dr. Thomas Schinecker, CEO of Roche, appointed President, effective January 1, 2025. |
| IFPMA Vice-President | Rob Davis, CEO of MSD, appointed as Vice-President. |
| Outgoing President | Dr. Albert Bourla completed his term as IFPMA President. |
| Schinecker's Previous Role | Served as IFPMA Vice-President for 2 years. |
| Roche's 2023 Sales | CHF 58.7 billion, a 1% increase despite decline in COVID-19-related sales. |
| Key Products in 2023 | Vabysmo, Columvi, Lunsumio, Alecensa, and Inavolisib. |
| Strategic Partnerships | Collaborations with Alnylam (high blood pressure) and Telavant (inflammatory bowel disease). |
| Focus Areas | Digital solutions, AI in drug development, diagnostics innovations (e.g., Elecsys IL-6). |
| Roche's Global Presence | Over 100,000 employees; leadership in oncology, neuroscience, ophthalmology, and diagnostics. |